Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ALOX5 | P09917 | 3/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL931218 | 0.98 | HPGD (0.53) | HPGDALOX5TP53HSD11B1ALDH1A1 | |
| SCHEMBL885302 | 0.98 | HPGD (0.53) | HPGDALOX5TP53HSD11B1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL5392447 | 0.95 | HPGD (0.52) | HPGDALOX5TP53HSD11B1ALDH1A1 | |
| SCHEMBL930589 | 0.95 | — | — | |
| SCHEMBL26294 | 0.90 | — | — | |
| SCHEMBL2752775 | 0.88 | SIGMAR1 (0.46) | HPGDALOX5MEN1KMT2A | |
| Hydrochloric Acid SCHEMBL4553434 | 0.87 | — | — | |
| SCHEMBL9100 | 0.86 | SIGMAR1 (0.50) | HPGDALOX5MEN1KMT2A | |
| SCHEMBL4677733 | 0.86 | KDM5A (0.50) | HPGDALOX5TDP1MEN1KMT2A | |
| SCHEMBL8392478 | 0.86 | SIGMAR1 (0.50) | HPGDALOX5MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 106 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119552093-A | Preparation method of key intermediate of poncirtinib phosphate | 济南鼎皓医药科技有限公司 | 2025-03-04 | — | — | CN | claimed |
| WO-2023125373-A1 | METHOD FOR PREPARING RUXOLITINIB AND INTERMEDIATE THEREOF | 江苏威凯尔医药科技有限公司 | 2023-07-06 | — | — | WO | claimed |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | EXELIXIS, INC (US) | 2011-05-26 | — | — | US | claimed |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | EXELIXIS, INC. | 2010-04-08 | — | — | US | claimed |
| US-20060079543-A1 | Anilino-pyrimidine analogs | WYETH (US) | 2006-04-13 | — | — | US | claimed |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-07-22 | — | — | US | claimed |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | PHARMACIA & UPJOHN COMPANY | 2004-06-10 | — | — | US | claimed |
| WO-2004018461-A2 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| WO-2004018428-A1 | ANTIBACTERIAL BENZOIC ACID DERIVATIVES | PHARMACIA & UPJOHN COMPANY LLC (US) | 2004-03-04 | — | — | WO | claimed |
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | WYETH (US) | 2003-01-23 | — | — | US | claimed |
| US-6451814-B1 | SUBSTITUTED 4-((4-AMINO-5-HYDROXYPHENYL)-OXY-)PIPERIDINE ANALOGS; METABOLIC DISORDERS; ANTIDIABETIC AGENTS; ATHERO-SCLEROSIS, GASTROINTESTINAL DISORDERS, GLAUCOMA, NEUROGENETIC INFLAMMATION, OCULAR HYPERTENSION AND FREQUENT URINATION | WYETH | 2002-09-17 | — | — | US | claimed |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | AMERICAN HOME PRODUCTS CORPORATION (US) | 2002-03-07 | — | — | US | claimed |
| WO-2002006229-A2 | HETEROCYCLIC BETA-3 ADRENERGIC RECEPTOR AGONISTS | WYETH (US) | 2002-01-24 | — | — | WO | claimed |
| EP-0748314-A1 | NOVEL TETRASUBSTITUTED IMIDAZOLE DERIVATIVES, METHOD FOR PREPARING SAME, RESULTING NOVEL INTERMEDIATES, USE THEREOF AS DRUGS, AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ROUSSEL UCLAF (FR) | 1996-12-18 | — | — | EP | claimed |
| CN-119552093-A | Preparation method of key intermediate of poncirtinib phosphate | 济南鼎皓医药科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| CN-119552093-A | Preparation method of key intermediate of poncirtinib phosphate | 济南鼎皓医药科技有限公司 | 2025-03-04 | — | — | CN | disclosed |
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | PMV PHARMACEUTICALS, INC. | 2024-04-11 | — | — | US | disclosed |
| EP-0007614-B1 | AN ANTIBACTERIAL COMPOSITION OF THIENAMYCIN-TYPE COMPOUND AND A DIPEPTIDASE INHIBITOR | MERCK & CO. INC. (US) | 1983-01-26 | — | — | EP | disclosed |
| EP-0010573-A1 | Novel Z-2-acylamino-3-monosubstituted propenic acids and their esters and salts, and processes for preparing them | MERCK & CO. INC. (US) | 1980-05-14 | — | — | EP | disclosed |
| EP-0007614-A1 | An antibacterial composition of thienamycin-type compound and a dipeptidase inhibitor | MERCK & CO. INC. (US) | 1980-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018045-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB2, ADRB1, ADRB3 | HPGD 825/4885ALOX5 2305/4885TP53 4790/4885 |
| US-20100087440-A1 | Phosphatidylinositol 3-Kinase Inhibitors and Methods of Their Use | PIK3CA, PIK3CB, PIK3CG | HPGD 1709/4885ALOX5 2682/4885TP53 263/4885 |
| US-20110123434-A1 | COMBINATION THERAPIES COMPRISING QUINOXALINE INHIBITORS OF P13K-ALPHA FOR USE IN THE TREATMENT OF CANCER | TP53, PHKG1, TNNI3K | HPGD 1433/4885ALOX5 4609/4885TP53 1/4885 |
| US-20060079543-A1 | Anilino-pyrimidine analogs | DPYD, TYMP, ADORA3 | HPGD 2648/4885ALOX5 2966/4885TP53 95/4885 |
| US-20020028832-A1 | Heterocyclic beta-3 adrenergic receptor agonists | ADRB1, ADRB3, ADRB2 | HPGD 947/4885ALOX5 2518/4885TP53 4644/4885 |
| US-20240116910-A1 | Heterocycles as WIP1 Inhibitors | WAPL, WHR1, G3BP1 | HPGD 1279/4885ALOX5 4315/4885TP53 29/4885 |
| US-20040142981-A1 | Antibacterial benzoic acid derivatives | GABRD, PHB1, GABBR1 | HPGD 1253/4885ALOX5 498/4885TP53 2699/4885 |
| US-20040110802-A1 | Antibacterial benzoic acid derivatives | GABRD, GABBR1, GABRA1 | HPGD 1657/4885ALOX5 413/4885TP53 2331/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.